Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus reuteri for H. pylori eradication
NCT05701683Phase 4Completed
- Sponsor
- Liaquat National Hospital & Medical College
- Start
- Nov 2019
- Primary completion
- Nov 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 4, randomised trial of lactobacillus reuteri in Helicobacter pylori infection (2 arms), sponsored by Liaquat National Hospital & Medical College. Primary endpoint: Helicobacter pylori eradication rate at 8 weeks. Started Nov 2019; status: completed.
02
Drugs
lactobacillus reuteri
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT05701683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05701683.